← All trials
NCT04857671
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 1, 2021
- Primary completion
- May 31, 2024
- Completion date
- Nov 30, 2024
- First posted
- Apr 23, 2021
- Last posted
- Jun 22, 2021
- Enrollment
- 60
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Northern Norway Regional Health AuthorityLead sponsor
- Norwegian University of Science and TechnologyCollaborator
- Nord Trøndelag Trust HNTStudy director
- Sandvika NevrosenterCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.